SOBOLEV SPACES.

Por ADAMS R A.
Publicado em S197

Significance of 801 monoclonal proteins detected during 7 years of screening in a district general hospital.

Por Smith, L, Adams, R A, Burston, C
Publicado em 1985

The incidence of monoclonal proteins during 7 years of screening in a District General Hospital.

Por Adams, R A, Smith, L, Pickering, P E
Publicado em 1984

GROWTH CHARACTERISTICS OF VIRUS-TRANSFORMED CELLS : MAXIMUM POPULATION DENSITY, INHIBITION BY NORMAL CELLS, SERUM REQUIREMENT, GROWTH IN SOFT AGAR, AND XENOGENEIC TRANSPLANTABILITY

Por Eagle, H., Foley, G. E., Koprowski, H., Lazarus, H., Levine, E. M., Adams, R. A.
Publicado em 1970

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience

Por Adams, R A, Meade, A M, Madi, A, Fisher, D, Kay, E, Kenny, S, Kaplan, R S, Maughan, T S
Publicado em 2009

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial

Por Madi, A, Fisher, D, Wilson, R H, Adams, R A, Meade, A M, Kenny, S L, Nichols, L L, Seymour, M T, Wasan, H, Kaplan, R, Maughan, T S
Publicado em 2012

A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised m...

Por Maughan, T S, Meade, A M, Adams, R A, Richman, S D, Butler, R, Fisher, D, Wilson, R H, Jasani, B, Taylor, G R, Williams, G T, Sampson, J R, Seymour, M T, Nichols, L L, Kenny, S L, Nelson, A, Sampson, C M, Hodgkinson, E, Bridgewater, J A, Furniss, D L, Roy, R, Pope, M J, Pope, J K, Parmar, M, Quirke, P, Kaplan, R
Publicado em 2014